Therefore, a combined immunotherapeutic approach of CAR-T cell therapy and PD-1 inhibition was hypothesized to overcome PD-1/PD-L1 pathway-mediated tumor immunosuppression and restore engineered cells’ ability. This evidence concerns the gene PDCD1 and neoplasm.